Artikler med mandater om offentlig tilgang - Bingchen HanLes mer
Tilgjengelige et eller annet sted: 22
Evaluation of MCF10A as a reliable model for normal human mammary epithelial cells
Y Qu, B Han, Y Yu, W Yao, S Bose, BY Karlan, AE Giuliano, X Cui
PloS one 10 (7), e0131285, 2015
Mandater: US National Institutes of Health
Breast cancer lung metastasis: Molecular biology and therapeutic implications
L Jin, B Han, E Siegel, Y Cui, A Giuliano, X Cui
Cancer biology & therapy 19 (10), 858-868, 2018
Mandater: US National Institutes of Health
FOXC1: an emerging marker and therapeutic target for cancer
B Han, N Bhowmick, Y Qu, S Chung, AE Giuliano, X Cui
Oncogene 36 (28), 3957-3963, 2017
Mandater: US National Institutes of Health
FOXC1 activates smoothened-independent hedgehog signaling in basal-like breast cancer
B Han, Y Qu, Y Jin, Y Yu, N Deng, K Wawrowsky, X Zhang, N Li, S Bose, ...
Cell reports 13 (5), 1046-1058, 2015
Mandater: US National Institutes of Health
FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer
B Han, B Zhou, Y Qu, B Gao, Y Xu, S Chung, H Tanaka, W Yang, ...
Oncogene 37 (10), 1399-1408, 2018
Mandater: US National Institutes of Health
Differentiation of human induced pluripotent stem cells to mammary-like organoids
Y Qu, B Han, B Gao, S Bose, Y Gong, K Wawrowsky, AE Giuliano, ...
Stem cell reports 8 (2), 205-215, 2017
Mandater: US National Institutes of Health
Diagnosis of basal-like breast cancer using a FOXC1-based assay
TW Jensen, T Ray, J Wang, X Li, WY Naritoku, B Han, F Bellafiore, ...
Journal of the National Cancer Institute 107 (8), djv148, 2015
Mandater: US National Institutes of Health
FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer
Y Jin, B Han, J Chen, R Wiedemeyer, S Orsulic, S Bose, X Zhang, ...
Annals of surgical oncology 21, 758-766, 2014
Mandater: US National Institutes of Health, National Natural Science Foundation of China
FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance
Y Yu-Rice, Y Jin, B Han, Y Qu, J Johnson, T Watanabe, L Cheng, N Deng, ...
Oncogene 35 (41), 5400-5411, 2016
Mandater: US National Institutes of Health
Characterization of primary human mammary epithelial cells isolated and propagated by conditional reprogrammed cell culture
L Jin, Y Qu, LJ Gomez, S Chung, B Han, B Gao, Y Yue, Y Gong, X Liu, ...
Oncotarget 9 (14), 11503, 2017
Mandater: US National Institutes of Health
Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer
S Chung, Y Jin, B Han, Y Qu, B Gao, AE Giuliano, X Cui
Cell Communication and Signaling 15, 1-9, 2017
Mandater: US National Institutes of Health
Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs
Y Qu, B Zhou, W Yang, B Han, Y Yu-Rice, B Gao, J Johnson, ...
Scientific reports 6 (1), 32007, 2016
Mandater: US National Institutes of Health
A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth
B Han, F Alonso-Valenteen, Z Wang, N Deng, TY Lee, B Gao, Y Zhang, ...
Molecular Therapy 30 (2), 672-687, 2022
Mandater: US Department of Defense, US National Institutes of Health
Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
SL Lim, L Xu, BC Han, P Shyamsunder, WJ Chng, HP Koeffler
PLoS One 15 (6), e0232068, 2020
Mandater: US Department of Defense, National Medical Research Council, Singapore …
FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort
J Johnson, M Choi, F Dadmanesh, B Han, Y Qu, Y Yu-Rice, X Zhang, ...
Oncotarget 7 (46), 75729, 2016
Mandater: US National Institutes of Health
FOXC1-induced Gli2 activation: A non-canonical pathway contributing to stemness and anti-Hedgehog resistance in basal-like breast cancer
B Han, Y Qu, Y Yu-Rice, J Johnson, X Cui
Molecular & cellular oncology 3 (3), e1131668, 2016
Mandater: US National Institutes of Health
Basal protein expression is associated with worse outcome and trastuzamab resistance in HER2+ invasive breast cancer
A Chung, M Choi, B Han, S Bose, X Zhang, L Medina-Kauwe, J Sims, ...
Clinical breast cancer 15 (6), 448-457. e2, 2015
Mandater: US National Institutes of Health
Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics
JD Sims, JM Taguiam, F Alonso-Valenteen, J Markman, H Agadjanian, ...
Journal of Controlled Release 271, 127-138, 2018
Mandater: US Department of Defense, US National Institutes of Health
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
B Gao, J Chen, B Han, X Zhang, J Hao, AE Giuliano, Y Cui, X Cui
Scientific Reports 11 (1), 2408, 2021
Mandater: US Department of Defense, US National Institutes of Health, National Natural …
Inhibition of lobuloalveolar development by FOXC1 overexpression in the mouse mammary gland
B Gao, Y Qu, B Han, Y Nagaoka, M Katsumata, N Deng, S Bose, L Jin, ...
Scientific Reports 7 (1), 14017, 2017
Mandater: US National Institutes of Health
Informasjon om publisering og finansiering fastsettes automatisk av et datamaskinprogram